𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α

✍ Scribed by Robert A. Figlin; Paul de Souza; David McDermott; Janice P. Dutcher; Anna Berkenblit; Alexandra Thiele; Mizue Krygowski; Andrew Strahs; Jay Feingold; Joseph Boni; Gary Hudes

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
324 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thirteen-year, long-term efficacy of int
Thirteen-year, long-term efficacy of interferon 2α and interleukin 2-based home therapy in patients with advanced renal cell carcinoma
✍ Jens Atzpodien; Reinhard Hoffmann; Marcus Franzke; Christian Stief; Thomas Wande 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Background: The goal of the current report was to demonstrate the long-term efficacy of outpatient subcutaneous (sc) interferon alpha (ifn-alpha) and sc interleukin 2 (il-2)-based combination regimens in patients with metastatic renal cell carcinoma. ## Methods: In three consecutive clinical t

Sequential treatment of patients with ad
Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon α2b
✍ S. Pomer; R. Thiele; V. Daniel; R. Weimer; H. Löhrke; V. Schirrmacher; G. Staehl 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 820 KB

Thirty patients with advanced renal cell carcinoma (RCC), 23 of whom had distant metastases in at least one organ, were entered after nephrectomy into a protocol involving vaccination with Newcastle disease virus (NDV)-modified autologous tumour material, with a subsequent induction week and repetit

A phase II trial of interferon-α and 5-f
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

Upfront, randomized, phase 2 trial of so
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis
✍ Eric Jonasch; Paul Corn; Lance C. Pagliaro; Carla L. Warneke; Marcella M. Johnso 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract ## BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low‐dose interferon‐alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). ## METHODS: Untreated patients with cle

A Phase II trial of intravenous gemcitab
A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH